Predictors of Severe COVID-19 Outcomes
PRESCO
1 other identifier
observational
494
1 country
8
Brief Summary
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 4, 2020
CompletedFirst Posted
Study publicly available on registry
May 14, 2020
CompletedStudy Start
First participant enrolled
May 28, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 23, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
September 23, 2021
CompletedMay 28, 2024
May 1, 2024
1.3 years
May 4, 2020
May 23, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Performance (discrimination / calibration) of models
Performance (discrimination / calibration) of models that predict the risk of development of ARDS and/or mortality among COVID-19 patients who present to the hospital for evaluation and treatment.
From date of study enrollment until the date of first documented ARDS diagnosis or date of death from any cause, whichever comes first, assessed up to study end (estimated at 3 months).
Eligibility Criteria
Participants confirmed positive for COVID-19.
You may qualify if:
- Participant or legally authorized representative willing and able to provide informed consent
- Receiving care at a participating site
- Age 18 years old or older
- U.S. Resident
- Confirmed positive for COVID-19
- Willing and able to comply with all study procedures
You may not qualify if:
- Self reported pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (8)
The University of Arizona
Tucson, Arizona, 85719, United States
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
University of Illinois at Chicago
Chicago, Illinois, 60607, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
Weill Cornell Medical College
New York, New York, 10065, United States
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Baylor College of Medicine
Houston, Texas, 77030, United States
Inova Health Care Services
Falls Church, Virginia, 22042, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Charlie Kim, PhD
Verily Life Sciences LLC
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 4, 2020
First Posted
May 14, 2020
Study Start
May 28, 2020
Primary Completion
September 23, 2021
Study Completion
September 23, 2021
Last Updated
May 28, 2024
Record last verified: 2024-05